BioSpace News Archive

Medicines360, a global nonprofit women’s health pharmaceutical organization, has appointed Tina Raine-Bennett , MD, MPH, FACOG, Chief Executive Officer (CEO), effective immediately, following a broad national search.

EpiVax, Inc. (“EpiVax”) is pleased to announce that Dr. Amy Rosenberg is leaving the FDA’s Division of Therapeutic Proteins, CDER, which she led for over 20 years, to join EpiVax as Senior Director of Immunology and Protein Therapeutics.

Optime Care, a nationally recognized pharmacy, distribution and patient management organization maximizing therapeutic opportunities for the treatment of orphan and rare disorders, announces the availability of Humatin™ (paromomycin sulfate) exclusively through Humatin Total Care.

Vivera Pharmaceuticals, Inc., congratulates its clinical research partner, Parexel International, on its $8.5 billion acquisition.

The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have entered into a license agreement granting worldwide exclusive rights to Pierre Fabre to develop and commercialize a family of human antibodies generated through the phage display human antibody Ymax®-ABL library owned by Y-Biologics.

Arcturus Therapeutics Holdings Inc. announced that the Company will participate in upcoming investor and scientific conferences.

CoImmune, Inc., a clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class yet more affordable cellular immunotherapies, today announced the appointments of Michael Fekete and Greg Tibbitts, to the Company’s board of directors.

Transcenta Holding Limited today announces that NMPA has accepted IND application of its anti-sclerostin monoclonal antibody TST002.

jCyte, Inc . announced the continued expansion of the company’s executive management team with the appointment of Adrian Morris as Chief Development Officer.

Sirnaomics, Inc. announced today that the company’s IND application for a systemic siRNA (small interfering RNA) drug candidate, STP707, received the U.S. Food and Drug Administration (FDA) acknowledgment “Study May Proceed” in patients with advanced solid tumors.